What is Anixa Biosciences, Inc.'s (ANIX) StockRank?

MoatMap's StockRank for Anixa Biosciences, Inc. (ANIX) is 4/100, with a Strong Sell signal. This is a composite score combining Quality (36), Value (24), and Momentum (20) factor ranks across MoatMap's 20,000+ stock universe.

Does Anixa Biosciences, Inc. have an economic moat?

Anixa Biosciences, Inc. (ANIX) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Anixa Biosciences, Inc. a buy, hold, or sell?

MoatMap's current signal for Anixa Biosciences, Inc. (ANIX) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Anixa Biosciences, Inc. in?

Anixa Biosciences, Inc. (ANIX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ANIX

STRONG SELLREMOVE

Anixa Biosciences, Inc. · Healthcare · United States · $91M · Avg Vol: $280K/d

StockRank

P/E (TTM)

—

ROE

-72.0%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Anixa Biosciences is a micro-cap biotechnology company with early-stage clinical assets and no commercialized products. It violates the Buffett and Terry Smith lenses due to its lack of recurring revenue, high cash burn, and highly speculative binary clinical trial outcomes.

COMPANY DESCRIPTION

Anixa Biosciences, Inc. is a biotechnology company focused on the development of cancer vaccines and novel CAR-T immunotherapies. The company's competitive moat is driven by its strategic research collaborations with premier institutions like the Cleveland Clinic and its proprietary platform targeting tissue-specific proteins. It operates as an innovative developer of preventative cancer vaccines, particularly for breast and ovarian cancers.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	210,000	0	0	—
EPS	-0.45	-0.32	-0.39	-0.34	—
Shares	31M	31M	32M	33M	+6.8%
Debt	221,000	175,000	232,000	204,000	-2.6%
Equity	29M	24M	20M	15M	-19.5%
Op CF	-6M	-6M	-7M	-7M	—
Inv CF	-11M	-6M	4M	5M	—
Fin CF	452,000	366,000	3M	2M	—

PRICE (1M)-21.3%

SMA 50SMA 200

$2.47

RSI (14)

31.8

52W High

$5.46

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-82.9%7.1

ROE

-72.0%11.3

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-19.0%17.9

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

0.01x86.2

Current Ratio

9.79x86.5

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

5.8x20.4

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

45%18.5

RS 6M

-60%17.3

SMA 50/200

0.84x20.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-3%19.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$91M

P/E (Forward)

-8.0x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANIX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ANIX	Anixa Biosciences, Inc.(you)	$91M	4	STRONG SELL
GANX	Gain Therapeutics, Inc.	$86M	3	STRONG SELL
SGMO	Sangamo Therapeutics, Inc.	$87M	3	STRONG SELL
ATYR	aTyr Pharma, Inc.	$82M	3	STRONG SELL
ALDX	Aldeyra Therapeutics, Inc.	$106M	4	STRONG SELL
AARD	Aardvark Therapeutics, Inc.	$92M	8	STRONG SELL
KALA	KALA BIO, Inc.	$104M	2	STRONG SELL
CGTX	Cognition Therapeutics, Inc.	$107M	6	STRONG SELL
ANVS	Annovis Bio, Inc.	$81M	1	STRONG SELL
PEPG	PepGen Inc.	$104M	7	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Anixa Biosciences, Inc. (ANIX) — Stock Score Summary

Anixa Biosciences, Inc. (ANIX) has a MoatMap StockRank of 4/100 based on Quality (36/100), Value (24/100), and Momentum (20/100) factor scores. The current signal is STRONG SELL. Anixa Biosciences is a micro-cap biotechnology company with early-stage clinical assets and no commercialized products. It violates the Buffett and Terry Smith lenses due to its lack of recurring revenue, high cash burn, and highly speculative binary clinical trial outcomes.

Key Financial Metrics

Price	$2.47
Market Cap	$91M
P/E (Forward)	-7.97
Price/Book	5.78
Return on Equity	-72.0%
Return on Invested Capital	-82.9%
Debt/Equity	1.39
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-3M

Anixa Biosciences, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Anixa Biosciences, Inc.’s (ANIX) StockRank?: MoatMap’s StockRank for Anixa Biosciences, Inc. (ANIX) is 4/100, with a Strong Sell signal. It is a composite of Quality (36), Value (24), and Momentum (20) factor ranks across MoatMap’s 20,000+ stock universe.
Does Anixa Biosciences, Inc. have an economic moat?: Anixa Biosciences, Inc. (ANIX) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Anixa Biosciences, Inc. a buy, hold, or sell?: MoatMap’s current signal for Anixa Biosciences, Inc. (ANIX) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Anixa Biosciences, Inc. in?: Anixa Biosciences, Inc. (ANIX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).